(COG AALL0932) Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)
The first goal of this study will be to determine if excellent outcomes (at least 95% 5-yr. disease free survival) are obtained. Another important goal of this study is to provide safe and standardized therapy to DS patients with SR-ALL, and to facilitate further study of this biologically and clinically unique subgroup. This trial will also incorporate prospective, standardized assessments of health related quality of life (HRQOL) among children with AR-ALL using patient-reported measurements. This data will serve as the basis for future screening and intervention strategies to minimize the morbidity of ALL and its therapy in the growing proportion of children with ALL that are cured.
Study Number: 

NCG 185010

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.